Eight Promising Medical Startups from the 2016 Nobel Laureate Medical Summit Roadshow File IPO Prospectus

The 2016 Nobel Prize Medicine Summit Innovation and Entrepreneurship Competition and Project Roadshow Was Grandly Held at the Shangri-La Hotel in Chengdu. Organized by the Nobel Laureates Medicine Summit Committee, Shinuo Capital, United Pharmaceutical Future Hub, and other institutions, the event featured a series of online and offline roadshows held for three consecutive times.

According to VCBeat (WeChat ID: vcbeat), nearly 30 innovative healthcare companies were selected from more than 300 projects that participated in presentations and exhibitions both domestically and internationally for this roadshow. Distinguished guests providing on-site commentary included Li Hebao, Partner at Shinuo Capital; Song Qingwei, Vice President of Jietong Group; and Zhang Shuaixin, Vice President of Kunming Pharmaceutical Group. Over the course of the four-hour roadshow, investors and judges engaged in comprehensive interactions and provided detailed feedback to the participating entrepreneurs.

The competition featured three award categories: the Most Investment-Worthy Award, the Most Promising Investment Award, and the International Innovation Award. Following a rigorous and meticulous evaluation by the judging panel, a total of 20 companies were honored with various awards. Below are theVCBeat (WeChat ID: vcbeat) has once again screened theSeveral...

Yikang Medical, headquartered in Beijing, serves both B-side enterprises (health management companies and health service providers) and C-side consumers, capturing over 6% of the offline medical service market in Beijing.

Through pre-consultation services and care plans, in-consultation assistance and accompaniment, and post-consultation follow-up services, the platform helps users access optimized care pathways and high-quality medical experiences in various forms. Backed by a robust team of medical resources and strong offline healthcare service capabilities, its business model involves coordinating medical resources with patient needs to deliver services, charging a 30% service fee.

All of the company’s product lines have achieved full operational status. Healthcare is a key sector receiving strong national support, currently growing at an annual rate of 150%. This roadshow aims to raise RMB 10 million in exchange for a 10% equity stake; mergers and acquisitions are also considered.

Medlai Company, based in Yangzhou, specializes in the R&D, manufacturing, and sales of disposable medical devices, including auto-disable and safety syringes. Its current product portfolio is protected by 2 invention patents, 20 utility model patents, and 2 global patents covering 48 countries. This year, the automated annual production capacity for safety injection needles reaches 200 million units, while that for safety infusion needles and safety blood collection needles stands at 40 million units.

Product Features: The safety needle utilizes UV-curable adhesive (eco-friendly) and features four locking points for enhanced security, effectively protecting nurses from needlestick injuries. Its compact design saves packaging space. The fixed needle tip orientation ensures ease of use. Minimal drug residue contributes to cost savings. Fully automated machine assembly guarantees consistent quality.

The company currently employs a distributor-based agency sales model, establishing long-term, mutually beneficial partnerships with agents to ensure stable and controllable distribution channels. It has registered over 100 general customers, including more than 30 high-quality clients in Europe and the United States. The company holds a one-third market share in both Brazil and Italy, and a 50% market share in Taiwan. The current fundraising plan seeks RMB 15 million in exchange for a 7% equity stake.

According to WHO data, China reports 2.82 million new cases of malignant tumors annually. Due to factors such as population aging, environmental pollution, and urbanization, the number of new cancer cases in China has been increasing year by year, currently rising to 3.5 million.

A major characteristic of targeted therapy is its action on specific molecular targets. As each patient’s condition varies, the choice of targeted drugs differs accordingly, enabling a degree of personalized cancer treatment. In terms of therapeutic modalities, over the past decade, the global landscape of anticancer pharmacotherapy has gradually shifted from conventional chemotherapy to targeted therapy, with the market share of targeted agents rising year by year. It is projected to capture the largest market share in the future, driven by market expansion resulting from the introduction of numerous new products.

Beijing Duoying Shidai Technology Co., Ltd. is one of the earliest teams in China to engage in the research and development of technologies for tumor diagnosis and treatment. Relying on the “Cell and Gene Therapy Pilot Scale Base of the Chinese Academy of Medical Sciences” and the “Institute of Biophysics, Chinese Academy of Sciences,” it has taken the lead in China in developing and applying personalized diagnostic and therapeutic technologies, such as cell- and gene-based therapies, for cancer patients.We have established collaborative platforms and technical exchange networks with dozens of large and medium-sized Grade 3A hospitals across China, conducting research and providing third-party services for autologous immune cell therapy, stem cell technology, allogeneic stem cells, and CAR-T technology.

Huasheng Gene entered the genetic testing field at an early stage. Leveraging its first-mover advantage, sustained R&D investment, and years of accumulated experience, it has promoted its services in more than 100 prefecture-level cities across Northeast, North, East, Central, and South China. By establishing a data collection system and network for tumor genomics big data and utilizing big data mining technologies, Huasheng Gene provides storage, mining, and analytical services for oncologists, patients, and pharmaceutical R&D institutions, ultimately delivering personalized precision medicine consulting services for cancer to end users.

The team comprises 9 PhDs, 15 master’s degree holders, and 45 bachelor’s degree holders. Its members are high-level professionals in technical fields such as bioinformatics, genetics, pharmacy, software engineering, and computer science, as well as in management and finance. This complementary professional structure ensures the smooth execution of various R&D tasks. In August 2015, the company was listed on the National Equities Exchange and Quotations (NEEQ) under the stock name “Huasheng Gene” and stock code 833190. As of the end of December 2015, the company had raised a total of RMB 74.4 million from the capital market.

Core business activities include the research and development of genetic data technologies, gene sequencing services, and the development, production, sales, and outsourcing of software. We anticipate that this business model will achieve a dominant market position within the next three to five years, demonstrating strong competitiveness. The company is seeking RMB 63 million in financing in exchange for a 15.76% equity stake.

This company specializes in the application and promotion of a green treatment model for oncology. Leveraging immune monitoring and immunomodulation technologies, and integrating multidisciplinary clinical collaboration, it guides precise targeted therapy to deliver highly customized treatment plans, thereby pioneering a high-quality chronic disease management model for cancer patients.

Mingdao’s founder first proposed a health management philosophy centered on immune modulation, introducing a proprietary quantitative immune evaluation, monitoring, and management system—the first such immune quantification framework to be proposed and applied globally. Based on this philosophy and core technologies, we offer the following products and services: quantitative monitoring of immune status, multi-level assessment of immune function, treatment and follow-up guided by immune indicators, and customized immunotherapy. By leveraging the quantitative immune system to monitor and manage immune status, we achieve the highest level of preventive care—addressing disease before it manifests—and truly realize personalized, precision medicine.This roadshow aims to raise RMB 20 million in exchange for a 10% equity stake.

This is a 4P health management platform—Prediction, Prevention, Personalization, and Intervention—built on big data of community residents’ health. Zhonghui Runfu Health Industry Management Co., Ltd. leverages internet technologies, embeds itself in communities, and delivers door-to-door services to create an O2O business model powered by localized “mobile internet + Internet of Things (IoT) + top-tier medical services.” It brings tertiary-grade hospital-level care into communities, serving as personal health consultants.

The primary pilot program is being conducted in Beijing, leveraging big data on resident health to enable community-based prevention and treatment. The market for personalized population health services is vast. The planned fundraising amount is RMB 10 million, in exchange for a 10% equity stake.

Jin Fuyi is a health and medical assistant application. Its company has consistently designed and developed smart terminal devices, focusing primarily on the health management of cardiovascular and cerebrovascular diseases—the most prevalent conditions among patients in China. By building a cloud-plus-edge solution, it provides one-stop, high-quality health management services that are scalable for widespread adoption.

Product R&D is nearing completion. Funding stage: Pre-A; Amount: RMB 10–20 million; Equity offered: 20%–25%. Funds will be used for mass production, market expansion, system operations, and new product development. All targets are expected to be achieved within 12 months. Sales channels will be established through both online and offline platforms.

The company’s first- and second-generation products have completed medical device registration. The first-generation product is in mass production, while the second-generation product is in small-batch production. Prototypes of the third-generation product have been developed. Meanwhile, system operational testing for the cloud platform has been completed, supporting concurrent access by up to 100,000 users.

According to statistics from the National Health and Family Planning Commission, of the 2 million new stroke patients in China each year, fewer than one-fifth receive scientific rehabilitation treatment. Over 80% of stroke patients lose hope for recovery. Furthermore, the number of stroke patients is projected to reach 32 million by 2030. The rehabilitation robots launched by the company hold immense market potential, with the potential to achieve a market share of over 50%.

Due to the significant challenges in hand rehabilitation for stroke patients, many companies struggle to develop effective rehabilitation devices. Ruihan Medical’s rehabilitation robot, launched after years of research and development, has achieved an overall efficacy rate of 80%.

The Ruihan Type I Rehabilitation Robot, developed and manufactured by the company, is currently scarce in the market and offers advantages such as high safety, effective rehabilitation outcomes, and low treatment costs. Furthermore, the company’s product targets hand rehabilitation for stroke patients, a segment that remains largely a blue ocean in the domestic Chinese market. Operating under a business model combining direct sales and leasing, the product is currently in the prototype development and production phase. The company plans to raise RMB 10 million in exchange for a 10% equity stake.

Note: VCBeat (WeChat ID: vcbeat) has been following up with and providing in-depth coverage of the outstanding healthcare startups that participated in this roadshow. Stay tuned!